Shares of Pharming Group (NASDAQ:PHAR - Get Free Report) saw strong trading volume on Friday . 2,626 shares traded hands during mid-day trading, a decline of 46% from the previous session's volume of 4,869 shares.The stock last traded at $8.72 and had previously closed at $8.30.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price target on shares of Pharming Group in a research report on Thursday.
View Our Latest Stock Report on PHAR
Pharming Group Trading Up 4.8 %
The stock has a market cap of $590.12 million, a PE ratio of -45.89 and a beta of 0.15. The stock's fifty day moving average price is $8.03 and its 200 day moving average price is $8.56. The company has a quick ratio of 2.65, a current ratio of 3.39 and a debt-to-equity ratio of 0.40.
Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The business had revenue of $74.09 million during the quarter, compared to the consensus estimate of $71.95 million. During the same period in the previous year, the business posted $0.02 EPS. On average, sell-side analysts forecast that Pharming Group will post -0.15 EPS for the current year.
Institutional Trading of Pharming Group
An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its stake in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 41,110 shares of the company's stock after buying an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.06% of Pharming Group worth $339,000 as of its most recent SEC filing. 0.03% of the stock is currently owned by institutional investors and hedge funds.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Stories
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
